Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:MBX OTCMKTS:NWPHF NASDAQ:SBTX OTCMKTS:WIZP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMBXMBX Biosciences$14.40-1.2%$13.13$4.81▼$27.50$483.75MN/A324,482 shs215,057 shsNWPHFNewron Pharmaceuticals$9.36$9.36$9.10▼$12.00$167.08M0.53600 shsN/ASBTXSilverback Therapeutics$11.12-4.3%$16.44$2.80▼$8.97$400.97M0.6337,931 shs4.88 million shsWIZPMawson Infrastructure Group$0.41-1.9%$0.47$0.07▼$1.45$196.96M1.77141,517 shs114,459 shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMBXMBX Biosciences-3.45%-5.20%+5.96%+6.82%+1,456,999,900.00%NWPHFNewron Pharmaceuticals0.00%0.00%0.00%0.00%+2.86%SBTXSilverback Therapeutics0.00%-13.99%-32.36%-20.03%-10.48%WIZPMawson Infrastructure Group0.00%-4.03%-2.76%-29.60%-68.85%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationMBXMBX Biosciences2.3171 of 5 stars3.50.00.00.02.21.70.6NWPHFNewron PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AWIZPMawson Infrastructure GroupN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMBXMBX Biosciences 3.00Buy$37.63161.28% UpsideNWPHFNewron Pharmaceuticals 0.00N/AN/AN/ASBTXSilverback Therapeutics 0.00N/AN/AN/AWIZPMawson Infrastructure Group 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest NWPHF, SBTX, WIZP, and MBX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/5/2025MBXMBX BiosciencesMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.007/16/2025MBXMBX BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$38.00(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMBXMBX BiosciencesN/AN/AN/AN/AN/AN/ANWPHFNewron Pharmaceuticals$6.82M24.50N/AN/A$0.21 per share44.57SBTXSilverback TherapeuticsN/AN/AN/AN/A$7.41 per shareN/AWIZPMawson Infrastructure GroupN/AN/AN/AN/A$0.03 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMBXMBX BiosciencesN/A-$4.54N/AN/AN/AN/AN/AN/AN/ANWPHFNewron Pharmaceuticals-$17.63MN/A0.00N/AN/AN/AN/AN/AN/ASBTXSilverback Therapeutics-$89.48M-$2.42N/A∞N/AN/A-29.62%-28.20%N/AWIZPMawson Infrastructure Group-$3.45M-$0.33N/AN/AN/AN/AN/A-85.32%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMBXMBX BiosciencesN/AN/AN/AN/AN/ANWPHFNewron PharmaceuticalsN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/AN/AWIZPMawson Infrastructure GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMBXMBX BiosciencesN/AN/AN/ANWPHFNewron PharmaceuticalsN/AN/AN/ASBTXSilverback TherapeuticsN/A67.8767.87WIZPMawson Infrastructure GroupN/A1.131.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMBXMBX BiosciencesN/ANWPHFNewron PharmaceuticalsN/ASBTXSilverback Therapeutics74.89%WIZPMawson Infrastructure GroupN/AInsider OwnershipCompanyInsider OwnershipMBXMBX Biosciences52.19%NWPHFNewron PharmaceuticalsN/ASBTXSilverback Therapeutics34.40%WIZPMawson Infrastructure GroupN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMBXMBX Biosciences3633.59 millionN/AN/ANWPHFNewron Pharmaceuticals2217.85 millionN/ANot OptionableSBTXSilverback Therapeutics8336.06 million23.65 millionNot OptionableWIZPMawson Infrastructure Group2486.32 millionN/ANot OptionableNWPHF, SBTX, WIZP, and MBX HeadlinesRecent News About These CompaniesH.C. Wainwright Sticks to Their Hold Rating for Mawson Infrastructure Group (MIGI)April 2, 2025 | markets.businessinsider.comMawson Infrastructure releases 2025 company presentationJanuary 28, 2025 | markets.businessinsider.comMawson Infrastructure names William Regan as CFOJanuary 17, 2025 | markets.businessinsider.comMawson Infrastructure reports December revenue $5.26M, up 7% month/monthJanuary 14, 2025 | markets.businessinsider.comMawson Infrastructure executes new customer agreementJanuary 7, 2025 | markets.businessinsider.comMawson Infrastructure Group Inc (MIGI) Stock Trading RecapDecember 10, 2024 | bovnews.comBCreditors file Chapter 11 involuntary petition against Mawson Infrastructure, latter vows to 'vigorously defend' itselfDecember 6, 2024 | bizjournals.comWhy Is Mawson Infrastructure Group Inc (MIGI) Stock Lagging Behind -56.76% from Its 50-Day SMA?December 6, 2024 | bovnews.comBMawson Infrastructure reports August revenue $4.44M; digital colocation business up 166% Y/YSeptember 16, 2024 | seekingalpha.comMawson Infrastructure Group Inc (MIGI) Stock: More Strategic Than Meets the EyeAugust 24, 2024 | bovnews.comBMawson Infra Gr (NASDAQ:MIGI) Stock, Short Interest ReportAugust 14, 2024 | benzinga.comMawson Infrastructure Group adds new customer at Midland bitcoin facilityDecember 20, 2023 | bizjournals.comMawson announces agreement for half of Midland bitcoin facility capacityOctober 19, 2023 | bizjournals.comMawson Infrastructure reports BTC production of 69 in July, down 3% M/MAugust 24, 2023 | seekingalpha.comH.C. Wainwright Sticks to Its Buy Rating for Mawson Infrastructure Group (MIGI)August 24, 2023 | markets.businessinsider.comMawson Infrastructure Group Inc. Invites Submission of Indication of Interest for its BTC Hosting and HPC Co-location ServicesJuly 25, 2023 | technews.tmcnet.comTMawson Infrastructure Group Inc. Announces Monthly Operational Update for June 2023July 19, 2023 | businesswire.comMawson Infrastructure Group Inc. Announces Monthly Operational Update for May 2023June 14, 2023 | technews.tmcnet.comTMawson Infrastructure Group names new president, CEOMay 22, 2023 | bizjournals.comWith Significant Increases In Megawatt Capacity And Bitcoin Production, Mawson Infrastructure Group (NASDAQ: MIGI) May Attract More Bitcoin Mining InvestorsApril 11, 2023 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNWPHF, SBTX, WIZP, and MBX Company DescriptionsMBX Biosciences NYSE:MBX$14.40 -0.17 (-1.17%) Closing price 04:00 PM EasternExtended Trading$14.40 -0.01 (-0.03%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.Newron Pharmaceuticals OTCMKTS:NWPHF$9.36 0.00 (0.00%) As of 08/29/2025Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focus on the development of novel therapies for the treatment of central nervous system (CNS) and pain in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, Switzerland, the United Kingdom, the United States of America, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan, and South Korea. The company's product pipeline includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. In addition, it has a strategic partnership with Zambon for the commercialization of safinamide; and license agreement with Meiji Seika Pharma Co., Ltd., for research, develop, manufacture, and marketing of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.Silverback Therapeutics NASDAQ:SBTX$11.12 -0.50 (-4.30%) As of 09/2/2025Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Mawson Infrastructure Group OTCMKTS:WIZP$0.41 -0.01 (-1.94%) As of 08/29/2025Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company is headquartered in North Sydney, Australia. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Loop Industries Insiders Buy Stock, Signal Confidence in Outlook Joby Aviation's Pullback: A Gift for Investors Who See the Future Opera Limited Stock Set to End 2025 on a High Note Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
